Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100

Thermo Fisher Scientific Inc. (TMO) Operating cash flow

Alert me on Operating cash flow

Thermo Fisher Scientific Inc.'s operating cash flow for fiscal 2025 was $7.8B, down 9.80% from $8.7B in fiscal 2024. Over the twelve months to 30 June 2026 it was $9.0B. Over the past ten years it has ranged from $2.9B (fiscal 2015) to $9.3B (fiscal 2021); the current reading is higher than 55% of that period. Thermo Fisher Scientific Inc. ranks 1st of 52 Diagnostics & Research companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $7.8B (9.80%)
FY2024 $8.7B 3.10%
FY2023 $8.4B (8.17%)
FY2022 $9.2B (1.70%)
FY2021 $9.3B 12.34%
FY2020 $8.3B 66.68%
FY2019 $5.0B 9.47%
FY2018 $4.5B 13.43%
FY2017 $4.0B 22.93%
FY2016 $3.3B 10.74%

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $2.1B 78.27%
Mar 2026 $1.2B (65.52%)
Dec 2025 $3.5B 54.40%
Sep 2025 $2.2B 60.04%
42 more quarters

Against its own ten years

Low $2.9B High $9.3B
Ten-year median $7.8B
Current reading's percentile 55

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on TMO